236 related articles for article (PubMed ID: 11205137)
1. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Youdim MB; Weinstock M
Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs.
Weinstock M; Kirschbaum-Slager N; Lazarovici P; Bejar C; Youdim MB; Shoham S
Ann N Y Acad Sci; 2001 Jun; 939():148-61. PubMed ID: 11462767
[TBL] [Abstract][Full Text] [Related]
4. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression.
Weinstock M; Poltyrev T; Bejar C; Youdim MB
Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501
[TBL] [Abstract][Full Text] [Related]
5. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
6. Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor.
Maruyama W; Weinstock M; Youdim MB; Nagai M; Naoi M
Neurosci Lett; 2003 May; 341(3):233-6. PubMed ID: 12697291
[TBL] [Abstract][Full Text] [Related]
7. Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task.
Buccafusco JJ; Terry AV; Goren T; Blaugrun E
Neuroscience; 2003; 119(3):669-78. PubMed ID: 12809688
[TBL] [Abstract][Full Text] [Related]
8. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Yogev-Falach M; Amit T; Bar-Am O; Weinstock M; Youdim MB
FASEB J; 2002 Oct; 16(12):1674-6. PubMed ID: 12206996
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
10. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Youdim MB; Amit T; Bar-Am O; Weinstock M; Yogev-Falach M
Ann N Y Acad Sci; 2003 May; 993():378-86; discussion 387-93. PubMed ID: 12853332
[TBL] [Abstract][Full Text] [Related]
11. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Youdim MB; Weinstock M
Mech Ageing Dev; 2002 Apr; 123(8):1081-6. PubMed ID: 12044957
[TBL] [Abstract][Full Text] [Related]
12. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
[TBL] [Abstract][Full Text] [Related]
13. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
Youdim MB; Wadia A; Tatton W; Weinstock M
Ann N Y Acad Sci; 2001 Jun; 939():450-8. PubMed ID: 11462801
[TBL] [Abstract][Full Text] [Related]
14. The neurochemical and behavioral effects of the novel cholinesterase-monoamine oxidase inhibitor, ladostigil, in response to L-dopa and L-tryptophan, in rats.
Sagi Y; Driguès N; Youdim MB
Br J Pharmacol; 2005 Oct; 146(4):553-60. PubMed ID: 16086033
[TBL] [Abstract][Full Text] [Related]
15. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
[TBL] [Abstract][Full Text] [Related]
16. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Yogev-Falach M; Bar-Am O; Amit T; Weinreb O; Youdim MB
FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
[TBL] [Abstract][Full Text] [Related]
17. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
19. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Bar-Am O; Weinreb O; Amit T; Youdim MB
J Mol Neurosci; 2009 Feb; 37(2):135-45. PubMed ID: 18751929
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.
Huang W; Chen Y; Shohami E; Weinstock M
Eur J Pharmacol; 1999 Feb; 366(2-3):127-35. PubMed ID: 10082192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
